A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa

The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)

Study Overview

• Status: Recruiting
• Conditions: Hidradenitis Suppurativa
• Intervention / Treatment: Drug: Bimekizumab

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: UCB Cares; Phone Number: 001 844 599 2273
• Study Contact Backup: Name: UCB Cares; Phone Number: +18445992273; Email: ucbcares@ucb.com

Study Locations

• Germany
  • Berlin, Germany
    • Recruiting
    • Hs0006 40326
  • Mainz, Germany
    • Recruiting
    • Hs0006 40747
• Poland
  • Warsaw, Poland
    • Recruiting
    • Hs0006 40761
  • Warsaw, Poland
    • Recruiting
    • Hs0006 40625
  • Wroclaw, Poland
    • Recruiting
    • Hs0006 40095
  • Wroclaw, Poland
    • Recruiting
    • Hs0006 40845
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85006
      • Recruiting
      • Hs0006 50175
  • California
    • Roseville, California, United States, 95661
      • Recruiting
      • Hs0006 50708
    • Sacramento, California, United States, 95815
      • Recruiting
      • Hs0006 50684
  • District of Columbia
    • Washington D.C., District of Columbia, United States, 20010
      • Recruiting
      • Hs0006 50707
  • Florida
    • Miami, Florida, United States, 33136
      • Recruiting
      • Hs0006 50199
  • Michigan
    • Clarkston, Michigan, United States, 48346
      • Recruiting
      • Hs0006 50178
    • Fort Gratiot, Michigan, United States, 48059
      • Recruiting
      • Hs0006 50710
    • Troy, Michigan, United States, 48084
      • Recruiting
      • Hs0006 50711
  • New York
    • New York, New York, United States, 10023
      • Recruiting
      • Hs0006 50712
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27516
      • Recruiting
      • Hs0006 50706
  • Ohio
    • Fairborn, Ohio, United States, 45324
      • Recruiting
      • Hs0006 50202
  • Texas
    • Arlington, Texas, United States, 76011
      • Recruiting
      • Hs0006 50201

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Study participant must be 12 to <18 years of age at the time of informed consent/assent, at Tanner stage 2 or more, for the first 8 participants only, followed by also including participants ≥9 to <18 years of age at Tanner stage 2 or more.
• Study participant must have a diagnosis of HS for at least 6 months prior to the Baseline Visit.
• Study participant must have moderate to severe HS, defined as a total of ≥5 inflammatory lesions (ie, the sum of abscesses and inflammatory nodules), as assessed at both the Screening and Baseline Visits.
• Study participant must have HS lesions present in at least 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or III, as assessed at both the Screening and Baseline Visits.
• Study participant must have had a history of inadequate response to a course of a systemic antibiotic for treatment of HS
• Study participant must weigh ≥30kg at the Screening Visit.

Exclusion Criteria:

• Study participant has a draining tunnel count of >20 at either the Screening or Baseline Visits.
• Study participant has experienced primary failure (no response within 12 weeks) to 1 or more IL 17 biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier.
• Study participant has previously participated in this study or has received previous therapy with bimekizumab.
• Study participant has a history of IBD or symptoms suggestive of IBD.
• History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
• Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)
• Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments
• Study participant has the presence of active suicidal ideation, or positive suicide behavior,
• Study participant diagnosed with severe depression in the past 6 months prior to the Screening Visit.
• Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Bimekizumab; Study participants will receive a bimekizumab dose which is weight-dependent.	Drug: Bimekizumab; Bimekizumab will be administered at pre-specified timepoints.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Geometric Mean Plasma bimekizumab concentrations at Week 16	Plasma samples will be collected prior to dosing for measurement of plasma concentrations of bimekizumab at the specified timepoint.	At Week 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exposure-adjusted incidence rate of Treatment- Emergent Adverse Events (TEAEs) during the Initial Treatment Period	The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. An Adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to IMP.	From Baseline until end of the Initial Treatment Period (up to 16 weeks)
Exposure-adjusted incidence rate of Serious TEAEs during the Initial Treatment Period	The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. A SAE is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events	From Baseline until end of the Initial Treatment Period (up to 16 weeks)
Exposure-adjusted incidence rate of TEAEs leading to withdrawal during the Initial Treatment Period	The TEAEs adjusted by duration of exposure to study treatment are scaled such that it provides an incidence rate per 100 patient-years. If a participant has multiple events, the time of exposure will be calculated to first occurrence of the AE being considered. If a participant has no events, the total time at risk will be used. An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to IMP.	From Baseline until end of the Initial Treatment Period (up to 16 weeks)
Exposure-adjusted incidence rate of Selected Safety Topics of Interest (including incidence of infections [serious, opportunistic, fungal, and TB], IBD, and injection site reactions) over the Initial Treatment Period	Safety topics of interest for this study include events for which special monitoring will be for infections (serious, opportunistic, fungal, and tuberculosis [TB]), inflammatory bowel disease (IBD), and injection site reactions.	Up to Week 16
Mean Change from Baseline in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) at Week 16	Blood pressure (Systolic Blood Pressure and Diastolic Blood Pressure) will be measured in millimeters of mercury (mmHg).	Baseline and Week 16
Mean Change from Baseline in vital sign (Pulse rate) at Week 16	Pulse Rate will be measured in beats per minute (beats/min).	Baseline and Week 16
Mean Change from Baseline in Biochemistry Laboratory Analyses (glucose, potassium, sodium, calcium) at Weeks 4,12, and 16	Glucose, potassium, sodium and calcium will be measured in millimoles per liter (mmol/L).	Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Biochemistry Laboratory Analyses (total bilirubin and direct bilirubin, total protein, blood urea nitrogen, and creatinine) at Weeks 4,12, and 16	Biochemistry parameters (total bilirubin and direct bilirubin, total protein, blood urea nitrogen [BUN], and creatinine) will be measured in micromols per liter (μmol/L).	Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Biochemistry Laboratory Analyses (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase) at Weeks 4,12, and 16	Biochemistry parameters (alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) will be measured in units per liter (U/L).	Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Hematology Laboratory Analyses (hemoglobin) at Weeks 4,12, and 16	Hemoglobin will be measured in grams per liter (g/L).	Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Hematology Laboratory Analyses (hematocrit) at Weeks 4,12, and 16	Hematocrit will be measured in volume percentage (%) of red blood cells in blood.	Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Hematology Laboratory Analyses (platelets, leukocytes, neutrophils, lymphocytes, eosinophils, basophils, and monocytes) at Weeks 4, 12, and 16	Platelets, leukocytes, neutrophils, lymphocytes, eosinophils, basophils, and monocytes will be measured in number of blood cells per liter (10^9/L)	Baseline, Weeks 4, 12, and 16
Mean Change from Baseline in Hematology Laboratory Analyses (erythrocytes)	Erythrocytes will be measured in number of red blood cells per liter (10^12/L).	Baseline, Week 4, 12, and 16
Incidence rate for Positive, Negative, Missing Plasma Anti-Bimekizumab Antibodies at Baseline and Week 16	Positive, negative, and missing plasma anti-bimekizumab antibodies detection prior to and following IMP administration during the Initial Treatment Period.	Baseline and Week 16

Collaborators and Investigators

• Sponsor: UCB Biopharma SRL
• Investigators: Study Director: UCB Cares, 001 844 599 2273

Study record dates

Study Major Dates

• Study Start (Actual): April 7, 2025
• Primary Completion (Estimated): December 21, 2026
• Study Completion (Estimated): March 6, 2029

Study Registration Dates

• First Submitted: April 3, 2025
• First Submitted That Met QC Criteria: April 3, 2025
• First Posted (Actual): April 10, 2025

Study Record Updates

• Last Update Posted (Actual): March 27, 2026
• Last Update Submitted That Met QC Criteria: March 26, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Keywords: Bimekizumab; HS; Hidradenitis Suppurativa
• Additional Relevant MeSH Terms: Infections; Skin Diseases; Bacterial Infections; Bacterial Infections and Mycoses; Sweat Gland Diseases; Skin Diseases, Bacterial; Skin Diseases, Infectious; Suppuration; Hidradenitis; Skin and Connective Tissue Diseases; Hidradenitis Suppurativa; bimekizumab
• Other Study ID Numbers: HS0006; 2023-505323-31 (Registry Identifier: EU Clinical Trials); U1111-1316-5308 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
• IPD Sharing Time Frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
• IPD Sharing Access Criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No